EasySep™小鼠TIL（CD45）正选试剂盒
产品号 #07801_C
用于分离单个核细胞的密度梯度离心液
若您需要咨询产品或有任何技术问题，请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系
New catalog numbers, same high quality product! The catalog numbers for the 250 mL and 500 mL sizes have changed to Catalog #18060 and Catalog #18061, respectively. Catalog numbers for the 1000 mL and 3000 mL sizes remain unchanged; however, the bottles within these bundled formats may have labels with the old or new catalog numbers during this transition.
总览
Lymphoprep™作为Ficoll-Paque™ 的经济实惠替代品，可帮助从外周血、脐带血或骨髓中稳定地分离单个核细胞。使用该密度梯度离心液，可以从正常个体和患者的各种血液样本中快速、简便、稳定地分离细胞。您可以用 Lymphoprep™ 替代 Ficoll-Paque™，且无需更改现有方案，即可获得一致的细胞纯度和回收率。该密度梯度离心液可与 SepMate™ 和 RosetteSep™ 完全兼容。Lymphoprep™ 配方中含有泛影酸钠 (9.1% w/v) 和多糖 (5.7% w/v)，密度为 1.077 g/ml。
包含
• Sodium diatrizoate (9.1% w/v)
• Polysaccharide (5.7% w/v)
• Other ingredients
亚型
密度梯度离心液
细胞类型
单个核细胞
种属
人
样本来源
Bone Marrow，Cord Blood，Whole Blood
筛选方法
Negative
应用
细胞分选
品牌
Lymphoprep
研究领域
免疫
实验数据
产品说明书及文档
请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。
应用领域
本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。
相关材料与文献
技术资料 (9)
文献 (43)
Chemoproteomic development of SLC15A4 inhibitors with anti-inflammatory activity. Nature chemical biology 2024 aug
Abstract
SLC15A4 is an endolysosome-resident transporter linked with autoinflammation and autoimmunity. Specifically, SLC15A4 is critical for Toll-like receptors (TLRs) 7-9 as well as nucleotide-binding oligomerization domain-containing protein (NOD) signaling in several immune cell subsets. Notably, SLC15A4 is essential for the development of systemic lupus erythematosus in murine models and is associated with autoimmune conditions in humans. Despite its therapeutic potential, the availability of quality chemical probes targeting SLC15A4 functions is limited. In this study, we used an integrated chemical proteomics approach to develop a suite of chemical tools, including first-in-class functional inhibitors, for SLC15A4. We demonstrate that these inhibitors suppress SLC15A4-mediated endolysosomal TLR and NOD functions in a variety of human and mouse immune cells; we provide evidence of their ability to suppress inflammation in vivo and in clinical settings; and we provide insights into their mechanism of action. Our findings establish SLC15A4 as a druggable target for the treatment of autoimmune and autoinflammatory conditions.
NETosis and thrombosis in vaccine-induced immune thrombotic thrombocytopenia. Nature communications 2022 sep
Abstract
Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare yet serious adverse effect of the adenoviral vector vaccines ChAdOx1 nCoV-19 (AstraZeneca) and Ad26.COV2.S (Janssen) against COVID-19. The mechanisms involved in clot formation and thrombocytopenia in VITT are yet to be fully determined. Here we show neutrophils undergoing NETosis and confirm expression markers of NETs in VITT patients. VITT antibodies directly stimulate neutrophils to release NETs and induce thrombus formation containing abundant platelets, neutrophils, fibrin, extracellular DNA and citrullinated histone H3 in a flow microfluidics system and in vivo. Inhibition of NETosis prevents VITT-induced thrombosis in mice but not thrombocytopenia. In contrast, in vivo blockage of Fc$\gamma$RIIa abrogates both thrombosis and thrombocytopenia suggesting these are distinct processes. Our findings indicate that anti-PF4 antibodies activate blood cells via Fc$\gamma$RIIa and are responsible for thrombosis and thrombocytopenia in VITT. Future development of NETosis and Fc$\gamma$RIIa inhibitors are needed to treat VITT and similar immune thrombotic thrombocytopenia conditions more effectively, leading to better patient outcomes.
IL-6 drives T cell death to participate in lymphopenia in COVID-19. International immunopharmacology 2022 oct
Abstract
Lymphopenia is a common observation in patients with COVID-19. To explore the cause of T cell lymphopenia in the disease, laboratory results of 64 hospitalized COVID-19 patients were retrospectively analyzed and six patients were randomly selected to trace their changes of T lymphocytes and plasma concentration of IL-6 for the course of disease. Results confirmed that the T-cell lymphopenia, especially CD4+ T cell reduction in COVID-19 patients, was a reliable indicator of severity and hospitalization in infected patients. And CD4+ T cell count below 200 cells/$\mu$L predicts critical illness in COVID-19 patients. In vitro assay supported that exposure to key contributors (IL-1$\beta$, IL-6, TNF-$\alpha$ and IFN-$\gamma$) of COVID-19 cytokine storm caused substantial death of activated T cells. Among these contributors, IL-6 level was found to probably reversely correlate with T cell counts in patients. And IL-6 alone was potent to induce T cell reduction by gasderminE-mediated pyroptosis, inferring IL-6 took a part in affecting the function and status of T cells in COVID-19 patients. Intervention of IL-6 mediated T cell pryprotosis may effectively delay disease progression, maintain normal immune status at an early stage of infection.
更多信息
| 种属 | Human |
|---|---|
| Contains | • Sodium diatrizoate (9.1% w/v) • Polysaccharide (5.7% w/v) • Other ingredients |
| 样本来源 | Bone Marrow, Cord Blood, Whole Blood |
| Selection Method | Negative |
相关产品
-
RosetteSep™人总淋巴细胞富集抗体混合物免疫密度负选试剂混合物
-
SepMate™-15 (IVD)用于体外诊断(IVD)应用的密度梯度离心管
-
SepMate™-50 (IVD)用于体外诊断(IVD)应用的密度梯度离心管
LYMPHOPREP™ IS A STERILE, ENDOTOXIN-TESTED SOLUTION MANUFACTURED BY A ISO 9001:2015 CERTIFIED COMPANY.
